 for clinical trials. Nolan et al40
reviewed data from the Vascular Study Group of New England and showed a higher rate of stroke and death for
symptomatic patients treated with CAS compared with
those treated with CEA (5.1% with CAS vs 1.6% with
CEA; P Â¼ .001). Similarly, Hicks et al41 studied almost
52,000 carotid procedures in the VQI and